Literature DB >> 25461449

Cancer-like epigenetic derangements of human pluripotent stem cells and their impact on applications in regeneration and repair.

Jeffrey S Huo1, Stephen B Baylin2, Elias T Zambidis3.   

Abstract

A growing body of work has raised concern that many human pluripotent stem cell (hPSC) lines possess tumorigenic potential following differentiation to clinically relevant lineages. In this review, we highlight recent work characterizing the spectrum of cancer-like epigenetic derangements in human embryonic stem cells (hESC) and human induced pluripotent stem cells (hiPSC) that are associated with reprogramming errors or prolonged culture that may contribute to such tumorigenicity. These aberrations include cancer-like promoter DNA hypermethylation and histone marks associated with pluripotency, as well as aberrant X-chromosome regulation. We also feature recent work that suggests optimized high-fidelity reprogramming derivation methods can minimize cancer-associated epigenetic aberrations in hPSC, and thus ultimately improve the ultimate clinical utility of hiPSC in regenerative medicine.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 25461449      PMCID: PMC4262610          DOI: 10.1016/j.gde.2014.09.008

Source DB:  PubMed          Journal:  Curr Opin Genet Dev        ISSN: 0959-437X            Impact factor:   5.578


  54 in total

1.  Naive-like conversion overcomes the limited differentiation capacity of induced pluripotent stem cells.

Authors:  Arata Honda; Masanori Hatori; Michiko Hirose; Chizumi Honda; Haruna Izu; Kimiko Inoue; Ryutaro Hirasawa; Shogo Matoba; Sumie Togayachi; Hiroyuki Miyoshi; Atsuo Ogura
Journal:  J Biol Chem       Date:  2013-07-23       Impact factor: 5.157

2.  Clonal genetic and hematopoietic heterogeneity among human-induced pluripotent stem cell lines.

Authors:  Jason A Mills; Kai Wang; Prasuna Paluru; Lei Ying; Lin Lu; Aline M Galvão; Dongbin Xu; Yu Yao; Spencer K Sullivan; Lisa M Sullivan; Helen Mac; Amel Omari; Jyh-Chang Jean; Steve Shen; Adam Gower; Avi Spira; Gustavo Mostoslavsky; Darrell N Kotton; Deborah L French; Mitchell J Weiss; Paul Gadue
Journal:  Blood       Date:  2013-08-12       Impact factor: 22.113

3.  Derivation of novel human ground state naive pluripotent stem cells.

Authors:  Ohad Gafni; Leehee Weinberger; Abed AlFatah Mansour; Yair S Manor; Elad Chomsky; Dalit Ben-Yosef; Yael Kalma; Sergey Viukov; Itay Maza; Asaf Zviran; Yoach Rais; Zohar Shipony; Zohar Mukamel; Vladislav Krupalnik; Mirie Zerbib; Shay Geula; Inbal Caspi; Dan Schneir; Tamar Shwartz; Shlomit Gilad; Daniela Amann-Zalcenstein; Sima Benjamin; Ido Amit; Amos Tanay; Rada Massarwa; Noa Novershtern; Jacob H Hanna
Journal:  Nature       Date:  2013-10-30       Impact factor: 49.962

4.  Premature termination of reprogramming in vivo leads to cancer development through altered epigenetic regulation.

Authors:  Kotaro Ohnishi; Katsunori Semi; Takuya Yamamoto; Masahito Shimizu; Akito Tanaka; Kanae Mitsunaga; Keisuke Okita; Kenji Osafune; Yuko Arioka; Toshiyuki Maeda; Hidenobu Soejima; Hisataka Moriwaki; Shinya Yamanaka; Knut Woltjen; Yasuhiro Yamada
Journal:  Cell       Date:  2014-02-13       Impact factor: 41.582

5.  Human pluripotent stem cells with distinct X inactivation status show molecular and cellular differences controlled by the X-Linked ELK-1 gene.

Authors:  Tal Bruck; Ofra Yanuka; Nissim Benvenisty
Journal:  Cell Rep       Date:  2013-07-18       Impact factor: 9.423

Review 6.  Tumorigenicity as a clinical hurdle for pluripotent stem cell therapies.

Authors:  Andrew S Lee; Chad Tang; Mahendra S Rao; Irving L Weissman; Joseph C Wu
Journal:  Nat Med       Date:  2013-08-06       Impact factor: 53.440

Review 7.  X chromosome inactivation and epigenetic responses to cellular reprogramming.

Authors:  Derek Lessing; Montserrat C Anguera; Jeannie T Lee
Journal:  Annu Rev Genomics Hum Genet       Date:  2013-05-06       Impact factor: 8.929

8.  Proteomic and genomic approaches reveal critical functions of H3K9 methylation and heterochromatin protein-1γ in reprogramming to pluripotency.

Authors:  Rupa Sridharan; Michelle Gonzales-Cope; Constantinos Chronis; Giancarlo Bonora; Robin McKee; Chengyang Huang; Sanjeet Patel; David Lopez; Nilamadhab Mishra; Matteo Pellegrini; Michael Carey; Benjamin A Garcia; Kathrin Plath
Journal:  Nat Cell Biol       Date:  2013-06-09       Impact factor: 28.824

9.  AID stabilizes stem-cell phenotype by removing epigenetic memory of pluripotency genes.

Authors:  Ritu Kumar; Lauren DiMenna; Nadine Schrode; Ting-Chun Liu; Philipp Franck; Silvia Muñoz-Descalzo; Anna-Katerina Hadjantonakis; Ali A Zarrin; Jayanta Chaudhuri; Olivier Elemento; Todd Evans
Journal:  Nature       Date:  2013-06-26       Impact factor: 49.962

10.  Subtelomeric hotspots of aberrant 5-hydroxymethylcytosine-mediated epigenetic modifications during reprogramming to pluripotency.

Authors:  Tao Wang; Hao Wu; Yujing Li; Keith E Szulwach; Li Lin; Xuekun Li; I-Ping Chen; Ian S Goldlust; Stormy J Chamberlain; Ann Dodd; He Gong; Gene Ananiev; Ji Woong Han; Young-sup Yoon; M Katharine Rudd; Miao Yu; Chun-Xiao Song; Chuan He; Qiang Chang; Stephen T Warren; Peng Jin
Journal:  Nat Cell Biol       Date:  2013-05-19       Impact factor: 28.824

View more
  3 in total

1.  Epigallocatechin Gallate Inhibits Mouse Mesenchymal Stem Cell Differentiation to Adipogenic Lineage.

Authors:  Baldeep Chani; Veena Puri; Ranbir Chander Sobti; Sanjeev Puri
Journal:  J Stem Cells Regen Med       Date:  2016-05-30

2.  Base-Resolution Methylome of Retinal Pigment Epithelial Cells Used in the First Trial of Human Induced Pluripotent Stem Cell-Based Autologous Transplantation.

Authors:  Hiromitsu Araki; Fumihito Miura; Akira Watanabe; Chikako Morinaga; Fumiyo Kitaoka; Yuko Kitano; Noriko Sakai; Yumiko Shibata; Motoki Terada; So Goto; Shinya Yamanaka; Masayo Takahashi; Takashi Ito
Journal:  Stem Cell Reports       Date:  2019-09-26       Impact factor: 7.765

3.  Effect of resveratrol on drug resistance in colon cancer chemotherapy.

Authors:  Lu Huang; Sheng Zhang; Jun Zhou; Xiangzhou Li
Journal:  RSC Adv       Date:  2019-01-18       Impact factor: 4.036

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.